Amgen`s Biologic Amjevita (Adalimumab) Receives Suppl Approvals in US
JERSEY CITY, N.J., Aug. 12, 2024 /PRNewswire/ -- Celltrion USA, Inc., (Celltrion USA) today announced its FDA-approved biosimilar adalimumab-aaty, has been added to the Costco member prescription program. Adalimumab-aaty is a high-concentration (100mg/mL) and citrate-free biosimilar to Humira® (adalimumab).
For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local...
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
AbbVie inks immune disorder drug licensing deal with China`s FutureGen
AbbVie`s tight grip on Humira market raises concerns about biosimilars
Fresenius Kabi Usa's Generic Adalimumab-Aacf Receives Approval in US
Fresenius Kabi USA`s Idacio (adalimumab-aacf) Receives Suppl Approval in the U.S.
Republicans and Democrats on the Senate Judiciary Committee on Tuesday both acknowledged the need for further reforms on how pharma patents are reviewed and how the system functions.